Tumor Absorbed Dosimetry and Response of Radionuclide Therapy in Metastatic Neuroendocrine Tumor

#2069

Introduction: Increased tumour lesion absorbed dosimetry (TLAD) from peptide receptor radionuclide therapy (PRRT) is associated with neuroendocrine tumours (NET) response. Responses to PRRT might be impacted by NET grade, site of origin and use of concurrent chemotherapy.

Aim(s): We assessed the correlation of TLAD and response of PRRT in patients with metastatic NET.

Materials and methods: Pre and post PRRT 68Ga-DOTATATE PET and TLAD measured with SPECT after cycle one were retrospectively analysed. PRRT consisted of four cycles of 7.45GBq Lutetium octreotate. TLAD was correlated with 6-month response assessment including change in lesion diameter (LD), morphologic tumour volume (ATV), metabolic tumour volume (MTV) and SUV max/mean.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burge M,

Keywords: 68Ga-DOTATATE PET, Tumor Dosimetry, Response,